{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:21:40Z","timestamp":1760833300020,"version":"build-2065373602"},"reference-count":123,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":2808,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.breast.2011.08.138","type":"journal-article","created":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T10:21:52Z","timestamp":1317291712000},"page":"8-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bone health management in patients with breast cancer: Current standards and emerging strategies"],"prefix":"10.1016","volume":"21","author":[{"given":"Matti S.","family":"Aapro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2011.08.138_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11912-009-0005-7","article-title":"The decline in breast cancer incidence: real or imaginary?","volume":"11","author":"Kurian","year":"2009","journal-title":"Curr Oncol Rep"},{"year":"2009","series-title":"Breast cancer facts and figures 2009-2010","key":"10.1016\/j.breast.2011.08.138_bib2"},{"key":"10.1016\/j.breast.2011.08.138_bib3","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ejca.2008.11.018","article-title":"EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary","volume":"45","author":"Sant","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib4","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00000421-200212001-00003","article-title":"Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints","volume":"25","author":"Major","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib6","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib8","unstructured":"Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et\u00a0al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Presented at: American Society of Clinical Oncology 2009 Breast Cancer Symposium; October 8-10, 2009; San Francisco, CA [Abstract 213]."},{"key":"10.1016\/j.breast.2011.08.138_bib9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.breast.2011.08.138_bib11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group","volume":"332","author":"Cummings","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2011.08.138_bib12","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.breast.2011.08.138_bib14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2011.08.138_bib18","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib19","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A\u00a0comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2011.08.138_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib21","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2011.08.138_bib22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib23","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1200\/JCO.2007.15.4997","article-title":"Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer","volume":"26","author":"Saarto","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.breast.2011.08.138_bib26","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl. 1","key":"10.1016\/j.breast.2011.08.138_bib27","first-page":"S9","article-title":"Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II)","volume":"106","author":"Singh","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2011.08.138_bib28","first-page":"12","article-title":"Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application","volume":"11","author":"Cole","year":"2009","journal-title":"Medscape J Med"},{"key":"10.1016\/j.breast.2011.08.138_bib29","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","article-title":"Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study","volume":"60","author":"Cooper","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.breast.2011.08.138_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.smj.0000221637.90495.66","article-title":"Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting","volume":"99","author":"Downey","year":"2006","journal-title":"South Med J"},{"key":"10.1016\/j.breast.2011.08.138_bib31","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4158\/EP.12.5.522","article-title":"Medication persistence with weekly versus daily doses of orally administered bisphosphonates","volume":"12","author":"Ettinger","year":"2006","journal-title":"Endocr Pract"},{"issue":"suppl. 2","key":"10.1016\/j.breast.2011.08.138_bib32","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.bone.2005.11.013","article-title":"Adherence and persistence: impact on outcomes and health care resources","volume":"38","author":"Reginster","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.breast.2011.08.138_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11926-008-0021-x","article-title":"Compliance and persistence with osteoporosis therapies","volume":"10","author":"Silverman","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.breast.2011.08.138_bib34","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1185\/030079907X226069","article-title":"Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills","volume":"23","author":"Weiss","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"suppl.","key":"10.1016\/j.breast.2011.08.138_bib35","first-page":"698s","article-title":"Higher persistency with i.v. bisphosphonates in patients with bone metastasis","volume":"24","author":"Mangiapane","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib36","doi-asserted-by":"crossref","unstructured":"Brufsky A, Harker G, Beck JT, Carroll R, Jin L, Warsi G, et\u00a0al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX [Abstract 4083].","DOI":"10.1158\/0008-5472.SABCS-09-4083"},{"key":"10.1016\/j.breast.2011.08.138_bib37","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2011.08.138_bib38","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","article-title":"Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial","volume":"90","author":"Fuleihan","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.breast.2011.08.138_bib39","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","article-title":"Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment","volume":"95","author":"Hershman","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.breast.2011.08.138_bib41","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib42","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdp560","article-title":"Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK","volume":"21","author":"Logman","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2011.08.138_bib44","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2011.08.138_bib45","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib48","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2019446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.breast.2011.08.138_bib49","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/cncr.21886","article-title":"Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients","volume":"106","author":"Bria","year":"2006","journal-title":"Cancer"},{"year":"2011","series-title":"NCCN clinical practice guidelines in oncology: breast cancer. Version 2.2011","key":"10.1016\/j.breast.2011.08.138_bib50"},{"key":"10.1016\/j.breast.2011.08.138_bib51","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib52","unstructured":"Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, et\u00a0al. Adjuvant treatment with zoledronic acid in stage II\/III breast cancer. The AZURE trial (BIG 01\/04). Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX [Abstract S4-5]."},{"key":"10.1016\/j.breast.2011.08.138_bib53","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"issue":"suppl.","key":"10.1016\/j.breast.2011.08.138_bib54","first-page":"20s","article-title":"Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow","volume":"26","author":"Lin","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl. 1","key":"10.1016\/j.breast.2011.08.138_bib55","first-page":"S40","article-title":"Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer","volume":"106","author":"Rack","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl.","key":"10.1016\/j.breast.2011.08.138_bib56","first-page":"170s","article-title":"Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients","volume":"69","author":"Solomayer","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2011.08.138_bib57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib58","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib59","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"},{"issue":"suppl. 1","key":"10.1016\/j.breast.2011.08.138_bib60","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2011.08.138_bib61","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-007-0439-4","article-title":"Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club","volume":"18","author":"Body","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.breast.2011.08.138_bib62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib63","first-page":"562","article-title":"Recommendations of a Swiss expert group on the use of bisphosphonates in patients with solid tumors","volume":"10","author":"Rochlitz","year":"2010","journal-title":"Swiss Med Forum"},{"issue":"suppl. 5","key":"10.1016\/j.breast.2011.08.138_bib64","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/annonc\/mdq159","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Aebi","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib65","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib66","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","article-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.breast.2011.08.138_bib67","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bone.2004.06.017","article-title":"A\u00a0family history of fracture and fracture risk: a meta-analysis","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.breast.2011.08.138_bib68","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A\u00a0meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.breast.2011.08.138_bib69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A\u00a0meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.breast.2011.08.138_bib70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"year":"2010","series-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","key":"10.1016\/j.breast.2011.08.138_bib71"},{"key":"10.1016\/j.breast.2011.08.138_bib72","first-page":"1","article-title":"Prevention and management of osteoporosis","volume":"921","year":"2003","journal-title":"WHO"},{"key":"10.1016\/j.breast.2011.08.138_bib73","unstructured":"Kanis JA. FRAX\u00ae WHO fracture risk assessment tool. Web version 3.2. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; Available at: <http:\/\/www.shef.ac.uk\/FRAX\/>. [accessed 27.06.11]."},{"key":"10.1016\/j.breast.2011.08.138_bib74","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A\u00a0high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","article-title":"Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society","volume":"17","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.breast.2011.08.138_bib76","doi-asserted-by":"crossref","first-page":"M599","DOI":"10.1093\/gerona\/57.9.M599","article-title":"Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data","volume":"57","author":"Kelley","year":"2002","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.breast.2011.08.138_bib77","first-page":"101","article-title":"Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy","volume":"7","author":"Swenson","year":"2009","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib78","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.breast.2011.08.138_bib79","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib80","unstructured":"US Department of Health and Human Services. Denosumab safety FDA analysis. Proceedings of the August 13, 2009, meeting of the Reproductive Health Drugs Advisory Committee. Available at: <http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM179782.pdf. [accessed 27.06.11]."},{"key":"10.1016\/j.breast.2011.08.138_bib81","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1055\/s-0029-1224109","article-title":"Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis","volume":"41","author":"Anastasilakis","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.breast.2011.08.138_bib82","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00198-009-1145-1","article-title":"Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab","volume":"21","author":"Toulis","year":"2010","journal-title":"Osteoporos Int"},{"year":"2010","series-title":"Prolia 60 mg solution for injection [summary of product characteristics]","key":"10.1016\/j.breast.2011.08.138_bib83"},{"year":"2010","series-title":"Prolia\u2122 (denosumab) injection [package insert]","key":"10.1016\/j.breast.2011.08.138_bib84"},{"key":"10.1016\/j.breast.2011.08.138_bib85","unstructured":"[Prolia, injection (denosumab)]. Swiss agency for therapeutic products. Available at: <http:\/\/www.swissmedic.ch\/zulassungen\/00171\/00181\/01382\/index.html?lang=en>. [accessed 27.06.11]."},{"key":"10.1016\/j.breast.2011.08.138_bib86","unstructured":"Notice of decision for PrProlia\u2122. Health Canada. Available at: <http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/pdf\/prodpharma\/sbd-smd\/phase1-decision\/drug-med\/nd_ad_2010_prolia_121139-eng.pdf>. [accessed 27.06.11]."},{"issue":"suppl. 4","key":"10.1016\/j.breast.2011.08.138_bib87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2011.08.138_bib88","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women\u00a0with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib89","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1002\/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.0.CO;2-C","article-title":"Bisphosphonates and breast carcinoma: present and future","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib90","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1188\/09.CJON.701-710","article-title":"Bone metastases from advanced cancers: clinical implications and treatment options","volume":"13","author":"Fitch","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.breast.2011.08.138_bib91","first-page":"377","article-title":"Assessment and treatment of patients with malignant spinal cord compression","volume":"2","author":"Abrahm","year":"2004","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib92","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2005.00.067","article-title":"Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative\u2019s Neuro-Oncology Disease Site Group","volume":"23","author":"Loblaw","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib93","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib94","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib95","first-page":"CD003474","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.breast.2011.08.138_bib96","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in\u00a0patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib97","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib98","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib99","doi-asserted-by":"crossref","unstructured":"Zheng M, Rosen L, Gordon D, Kaminski M, Howell A, Belch A, et\u00a0al. Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases. Presented at: The 9th St. Gallen International Consensus Conference on Primary Therapy of Early Breast Cancer; January 26-29, 2005; St. Gallen, Switzerland [Abstract 104].","DOI":"10.1016\/S0960-9776(05)80140-7"},{"key":"10.1016\/j.breast.2011.08.138_bib100","unstructured":"Costa L, Chen Y-M. Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate. Presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX [Abstract 1071]."},{"key":"10.1016\/j.breast.2011.08.138_bib101","first-page":"CD002068","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases","author":"Wong","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.breast.2011.08.138_bib102","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib103","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib104","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"issue":"suppl.","key":"10.1016\/j.breast.2011.08.138_bib105","first-page":"694s","article-title":"Loading dose ibandronate in rapid pain management of metastatic bone disease (MBD)","volume":"24","author":"Pendharkar","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib106","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.breast.2011.08.138_bib107","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","article-title":"Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study","volume":"22","author":"Mancini","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib108","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of\u00a0bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2011.08.138_bib109","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.20602","article-title":"Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells","volume":"113","author":"Neville-Webbe","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib110","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1002\/1097-0142(20000615)88:12+<2952::AID-CNCR11>3.0.CO;2-M","article-title":"Markers of bone turnover in bone metastases","volume":"88","author":"Fontana","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib111","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib112","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2011.08.138_bib113","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2011.08.138_bib114","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.clinthera.2005.08.006","article-title":"Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom","volume":"27","author":"De Cock","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.breast.2011.08.138_bib115","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1185\/030079905X40472","article-title":"Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK","volume":"21","author":"Guest","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.breast.2011.08.138_bib116","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdl093","article-title":"Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases","volume":"17","author":"Botteman","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib117","first-page":"400","article-title":"Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients","volume":"36","author":"Paterson","year":"2008","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.breast.2011.08.138_bib118","doi-asserted-by":"crossref","unstructured":"Carter JA, Snedecor SJ, Kaura S, Botteman MF. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC). Presented at: 2011 ASCO Annual Meeting; June 3-7, 2011; Chicago, IL [Abstract 9025].","DOI":"10.1200\/jco.2011.29.15_suppl.9025"},{"key":"10.1016\/j.breast.2011.08.138_bib119","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"year":"2010","series-title":"Xgeva\u2122 (denosumab) injection [package insert]","key":"10.1016\/j.breast.2011.08.138_bib120"},{"key":"10.1016\/j.breast.2011.08.138_bib121","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et\u00a0al. Denosumab to prolong bone metastasis-free survival in men with castrate-resistant prostate cancer: results of a global phase 3, randomized, double-blind trial. Plenary Presentation at: AUA Annual Meeting; May 14-19, 2011; Washington, DC."},{"key":"10.1016\/j.breast.2011.08.138_bib122","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2011.08.138_bib123","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/sj.bjc.6605579","article-title":"Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in\u00a0vitro: evidence of synergistic interaction","volume":"102","author":"Neville-Webbe","year":"2010","journal-title":"Br J Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977611003225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977611003225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:28:36Z","timestamp":1760776116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977611003225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0960977611003225"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2011.08.138","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone health management in patients with breast cancer: Current standards and emerging strategies","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2011.08.138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}